Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Neural Circuitry of Novelty Salience Processing in Psychosis Risk: Association With Clinical Outcome.

Modinos G, Allen P, Zugman A, Dima D, Azis M, Samson C, Bonoldi I, Quinn B, Gifford GWG, Smart SE, Antoniades M, Bossong MG, Broome MR, Perez J, Howes OD, Stone JM, Grace AA, McGuire P.

Schizophr Bull. 2019 Sep 18. pii: sbz089. doi: 10.1093/schbul/sbz089. [Epub ahead of print]

PMID:
32227226
2.

Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review.

van der Steur SJ, Batalla A, Bossong MG.

Brain Sci. 2020 Feb 12;10(2). pii: E97. doi: 10.3390/brainsci10020097. Review.

3.

Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis.

Wilson R, Bossong MG, Appiah-Kusi E, Petros N, Brammer M, Perez J, Allen P, McGuire P, Bhattacharyya S.

Transl Psychiatry. 2019 Aug 22;9(1):203. doi: 10.1038/s41398-019-0534-2.

4.

Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies-PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice.

Tognin S, van Hell HH, Merritt K, Winter-van Rossum I, Bossong MG, Kempton MJ, Modinos G, Fusar-Poli P, Mechelli A, Dazzan P, Maat A, de Haan L, Crespo-Facorro B, Glenthøj B, Lawrie SM, McDonald C, Gruber O, van Amelsvoort T, Arango C, Kircher T, Nelson B, Galderisi S, Bressan R, Kwon JS, Weiser M, Mizrahi R, Sachs G, Maatz A, Kahn R, McGuire P; PSYSCAN Consortium .

Schizophr Bull. 2020 Feb 26;46(2):432-441. doi: 10.1093/schbul/sbz067.

5.

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review.

Batalla A, Janssen H, Gangadin SS, Bossong MG.

J Clin Med. 2019 Jul 19;8(7). pii: E1058. doi: 10.3390/jcm8071058. Review.

6.

Basic Self-Disturbances Related to Reduced Anterior Cingulate Volume in Subjects at Ultra-High Risk for Psychosis.

Bonoldi I, Allen P, Madeira L, Tognin S, Bossong MG, Azis M, Samson C, Quinn B, Calem M, Valmaggia L, Modinos G, Stone J, Perez J, Howes O, Politi P, Kempton MJ, Fusar-Poli P, McGuire P.

Front Psychiatry. 2019 May 10;10:254. doi: 10.3389/fpsyt.2019.00254. eCollection 2019.

7.

Acute effects of ∆9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype.

Bossong MG, van Hell HH, Schubart CD, van Saane W, Iseger TA, Jager G, van Osch MJP, Jansma JM, Kahn RS, Boks MP, Ramsey NF.

Eur Neuropsychopharmacol. 2019 Jun;29(6):766-776. doi: 10.1016/j.euroneuro.2019.03.010. Epub 2019 Apr 8.

PMID:
30975584
8.

Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.

Bossong MG, Antoniades M, Azis M, Samson C, Quinn B, Bonoldi I, Modinos G, Perez J, Howes OD, Stone JM, Allen P, McGuire P.

JAMA Psychiatry. 2019 Feb 1;76(2):199-207. doi: 10.1001/jamapsychiatry.2018.3252.

9.

The neuropsychopharmacology of cannabis: A review of human imaging studies.

Bloomfield MAP, Hindocha C, Green SF, Wall MB, Lees R, Petrilli K, Costello H, Ogunbiyi MO, Bossong MG, Freeman TP.

Pharmacol Ther. 2019 Mar;195:132-161. doi: 10.1016/j.pharmthera.2018.10.006. Epub 2018 Oct 19. Review.

10.

The acute effects of cannabis on human executive function.

Oomen PP, van Hell HH, Bossong MG.

Behav Pharmacol. 2018 Oct;29(7):605-616. doi: 10.1097/FBP.0000000000000426. Review.

PMID:
30199388
11.

Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.

Bhattacharyya S, Wilson R, Appiah-Kusi E, O'Neill A, Brammer M, Perez J, Murray R, Allen P, Bossong MG, McGuire P.

JAMA Psychiatry. 2018 Nov 1;75(11):1107-1117. doi: 10.1001/jamapsychiatry.2018.2309.

12.

Human Striatal Response to Reward Anticipation Linked to Hippocampal Glutamate Levels.

Bossong MG, Wilson R, Appiah-Kusi E, McGuire P, Bhattacharyya S.

Int J Neuropsychopharmacol. 2018 Jul 1;21(7):623-630. doi: 10.1093/ijnp/pyy011.

13.

Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second Cohort.

Allen P, Azis M, Modinos G, Bossong MG, Bonoldi I, Samson C, Quinn B, Kempton MJ, Howes OD, Stone JM, Calem M, Perez J, Bhattacharayya S, Broome MR, Grace AA, Zelaya F, McGuire P.

Schizophr Bull. 2018 Oct 17;44(6):1323-1331. doi: 10.1093/schbul/sbx169.

14.

The Salience of Reward.

Bossong MG, Kahn RS.

JAMA Psychiatry. 2016 Aug 1;73(8):777-8. doi: 10.1001/jamapsychiatry.2016.1134. No abstract available.

PMID:
27384314
15.

A systematic review of multisensory cognitive-affective integration in schizophrenia.

Tseng HH, Bossong MG, Modinos G, Chen KM, McGuire P, Allen P.

Neurosci Biobehav Rev. 2015 Aug;55:444-52. doi: 10.1016/j.neubiorev.2015.04.019. Epub 2015 May 5. Review.

PMID:
25956248
16.

Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum.

Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, Stokes PR.

Psychopharmacology (Berl). 2015 Aug;232(15):2723-9. doi: 10.1007/s00213-015-3915-0. Epub 2015 Mar 25.

17.

A systematic review of the antipsychotic properties of cannabidiol in humans.

Iseger TA, Bossong MG.

Schizophr Res. 2015 Mar;162(1-3):153-61. doi: 10.1016/j.schres.2015.01.033. Epub 2015 Feb 7. Review.

PMID:
25667194
18.

Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC).

Bossong MG, Jansma JM, Bhattacharyya S, Ramsey NF.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jul 3;52:53-69. doi: 10.1016/j.pnpbp.2013.11.017. Epub 2013 Dec 29. Review.

PMID:
24380726
19.

Default mode network in the effects of Δ9-Tetrahydrocannabinol (THC) on human executive function.

Bossong MG, Jansma JM, van Hell HH, Jager G, Kahn RS, Ramsey NF.

PLoS One. 2013 Jul 31;8(7):e70074. doi: 10.1371/journal.pone.0070074. Print 2013.

20.

The endocannabinoid system and emotional processing: a pharmacological fMRI study with ∆9-tetrahydrocannabinol.

Bossong MG, van Hell HH, Jager G, Kahn RS, Ramsey NF, Jansma JM.

Eur Neuropsychopharmacol. 2013 Dec;23(12):1687-97. doi: 10.1016/j.euroneuro.2013.06.009. Epub 2013 Aug 6.

Supplemental Content

Loading ...
Support Center